Acrivon Therapeutics, Inc.
ACRVHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeAcrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by. The company carries a $91.3M market cap, placing it firmly in the micro-cap category. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.
Market Cap
$91.3M
Beta
1.93
P/E (TTM)
—
P/E (Fwd)
-1.26
EPS (TTM)
$-1.88
EPS (Fwd)
$-1.69
ROE
-64.6%
ROA
-38.0%
Cash
$90.0M
Total Debt
$2.1M
Free CF
-$39.8M
52W Change
19.0%
Annual Financials
Cash vs Debt
Where ACRV stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, ACRV finished 25.00% above its 150-day moving average ($1.72) and 15.59% above its 200-day moving average ($1.86). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ACRV overbought or oversold?
At the September 3, 2026 close, ACRV's RSI(14) was 62.9, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $90.0M in cash and $2.1M in debt, ACRV maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$39.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -64.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
A beta of 1.93 means ACRV is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. With cash comfortably exceeding debt, ACRV has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Acrivon Therapeutics, Inc. and its sector.